CAICaris Life Sciences, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~47% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CAI's price assumes
Caris Life Sciences, Inc. has no trailing P/E on file, so the price is measured against sales instead: 9.14× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 0.26%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- +47%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 15.3
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 15.3
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 60.9
- EV / salestoday's price, trailing year to Jun 30, 2026
- 9.43
- Free cash flow, trailing twelve months
- $24M
- Market capitalisation282.6 million shares, counted Aug 3, 2026
- $9.04B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Biotechnology
The closest names by size in the same industry